KoreaBIO: "Vaccines Should Also Be Included as Eligible Items for Domestic Production Tax Credits"
KoreaBIO Submits Proposal to Ministry of Economy and Finance
"Contributing to Supply Chain Stability and Strengthening Health Security"
The bio industry has requested the government to include vaccines as eligible items for domestic production tax credits under the newly established Restriction of Special Taxation Act.
The Korea Biotechnology Industry Organization (KoreaBIO) announced on the 20th that it had submitted a proposal to the Ministry of Economy and Finance the previous day, calling for the inclusion of vaccines in the tax incentive scheme to maintain and expand the domestic vaccine production base and stabilize supply chains. The government is currently pursuing the establishment of “special taxation for promoting domestic production” in response to the strengthening of global protectionism, supply chain instability, and the need to expand the domestic production base.
Vaccines are critical health security products that can have an immediate impact on public health and epidemic response capabilities if supplies are interrupted. Securing sufficient domestic manufacturing capacity to ensure stable supply even in crisis situations is crucial. In particular, during the COVID-19 pandemic, it became evident that export restrictions between countries, supply chain bottlenecks, and lack of manufacturing facilities could directly impact people’s access to vaccines.
The domestic foundation for vaccine research and development is also being expanded. As of the end of 2023, at least 36 Korean companies reportedly have a total of 108 vaccine R&D pipelines. As of November last year, among the 279 vaccines certified by the World Health Organization (WHO) Prequalification (PQ) program, 23 were developed by Korean companies.
The fact that major vaccine manufacturing facilities are located outside the capital region is also cited as a reason for tax support. SK bioscience operates its main production facility in Andong, North Gyeongsang Province, while GC Green Cross has a core facility in Hwasun, South Jeolla Province. Expanding vaccine production can also lead to job creation in local communities and foster related industries.
The association believes that granting tax benefits to domestically produced vaccines will increase cost competitiveness and encourage companies to expand domestic investment. In the long term, such measures can serve as a policy tool to strengthen the domestic production base and promote reshoring—the return of overseas manufacturing facilities to Korea.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The association stated, “Vaccines should be included as eligible items for the domestic production tax credit, as this would enhance the cost competitiveness of domestic vaccine manufacturing, encourage companies to expand domestic production and investment, and simultaneously achieve vaccine supply chain stabilization, strengthening of health and economic security, the development of the bio materials and components industry, and the creation of local jobs.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.